-
41.发明申请STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 有权稳定的免疫调节剂RNA（SIMRA）化合物用于TLR7和TLR8公开(公告)号：US20130202584A1
公开(公告)日：2013-08-08
申请号：US13353905
申请日：2012-01-19
申请人： Ekambar R. Kandimalla , Tao Lan , Yukui Li , Dong Yu , Daqing Wang , Mallikarjuna Reddy Putta , Sudhir Agrawal
发明人： Ekambar R. Kandimalla , Tao Lan , Yukui Li , Dong Yu , Daqing Wang , Mallikarjuna Reddy Putta , Sudhir Agrawal
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： C07K14/665 , A61K31/713 , A61K39/0005 , A61K39/395 , A61K39/3955 , C12N15/117 , C12N2310/17 , C12N2310/315 , C12N2310/318 , C12N2310/3183 , C12N2310/321 , C12N2310/33 , C12N2310/331 , C12N2310/336 , C12N2310/3521
摘要： The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
摘要翻译： 本发明涉及稳定的寡核糖核苷酸作为免疫治疗应用的免疫调节剂的治疗用途。 具体地，本发明提供具有改进的核酸酶和核糖核酸酶稳定性的基于RNA的寡核糖核苷酸，并且通过TLR7和/或TLR8具有免疫调节活性。
-
42.发明授权Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 有权用于TLR7和TLR8的稳定免疫调节RNA（SIMRA）化合物公开(公告)号：US08759310B2
公开(公告)日：2014-06-24
申请号：US13353905
申请日：2012-01-19
申请人： Ekambar R. Kandimalla , Tao Lan , Yukui Li , Dong Yu , Daqing Wang , Mallikarjuna Reddy Putta , Sudhir Agrawal
发明人： Ekambar R. Kandimalla , Tao Lan , Yukui Li , Dong Yu , Daqing Wang , Mallikarjuna Reddy Putta , Sudhir Agrawal
CPC分类号： C07K14/665 , A61K31/713 , A61K39/0005 , A61K39/395 , A61K39/3955 , C12N15/117 , C12N2310/17 , C12N2310/315 , C12N2310/318 , C12N2310/3183 , C12N2310/321 , C12N2310/33 , C12N2310/331 , C12N2310/336 , C12N2310/3521
摘要： The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
摘要翻译： 本发明涉及稳定的寡核糖核苷酸作为免疫治疗应用的免疫调节剂的治疗用途。 具体地，本发明提供具有改进的核酸酶和核糖核酸酶稳定性的基于RNA的寡核糖核苷酸，并且通过TLR7和/或TLR8具有免疫调节活性。
-
43.发明申请STABILIZED IMMUNE MODULATORY RNA (SIMRA) COMPOUNDS FOR TLR7 AND TLR8 有权稳定的免疫调节剂RNA（SIMRA）化合物用于TLR7和TLR8公开(公告)号：US20080171712A1
公开(公告)日：2008-07-17
申请号：US11697422
申请日：2007-04-06
申请人： Ekambar R. Kandimalla , Tao Lan , Yukui Li , Dong Yu , Daqing Wang , Mallikarjuna Reddy Putta , Sudhir Agrawal
发明人： Ekambar R. Kandimalla , Tao Lan , Yukui Li , Dong Yu , Daqing Wang , Mallikarjuna Reddy Putta , Sudhir Agrawal
IPC分类号： A61K48/00 , A61K39/395
CPC分类号： C07K14/665 , A61K31/713 , A61K39/0005 , A61K39/395 , A61K39/3955 , C12N15/117 , C12N2310/17 , C12N2310/315 , C12N2310/318 , C12N2310/3183 , C12N2310/321 , C12N2310/33 , C12N2310/331 , C12N2310/336 , C12N2310/3521
摘要： The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
摘要翻译： 本发明涉及稳定的寡核糖核苷酸作为免疫治疗应用的免疫调节剂的治疗用途。 具体地，本发明提供具有改进的核酸酶和核糖核酸酶稳定性的基于RNA的寡核糖核苷酸，并且通过TLR7和/或TLR8具有免疫调节活性。
-
44.发明授权Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8 有权用于TLR7和TLR8的稳定免疫调节RNA（SIMRA）化合物公开(公告)号：US08106173B2
公开(公告)日：2012-01-31
申请号：US11697422
申请日：2007-04-06
申请人： Ekambar R. Kandimalla , Tao Lan , Yukui Li , Dong Yu , Daqing Wang , Mallikarjuna Reddy Putta , Sudhir Agrawal
发明人： Ekambar R. Kandimalla , Tao Lan , Yukui Li , Dong Yu , Daqing Wang , Mallikarjuna Reddy Putta , Sudhir Agrawal
CPC分类号： C07K14/665 , A61K31/713 , A61K39/0005 , A61K39/395 , A61K39/3955 , C12N15/117 , C12N2310/17 , C12N2310/315 , C12N2310/318 , C12N2310/3183 , C12N2310/321 , C12N2310/33 , C12N2310/331 , C12N2310/336 , C12N2310/3521
摘要： The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
摘要翻译： 本发明涉及稳定的寡核糖核苷酸作为免疫治疗应用的免疫调节剂的治疗用途。 具体地，本发明提供具有改进的核酸酶和核糖核酸酶稳定性的基于RNA的寡核糖核苷酸，并且通过TLR7和/或TLR8具有免疫调节活性。
-
45.发明申请POTENT MUCOSAL IMMUNE RESPONSE INDUCED BY MODIFIED IMMUNOMODULATORY OLIGONUCLEOTIDES 审中-公开改性免疫组化寡核苷酸诱导的轻度粘膜免疫应答公开(公告)号：US20110123540A1
公开(公告)日：2011-05-26
申请号：US12952868
申请日：2010-11-23
申请人： Daqing Wang , Ekambar Kandimalla , Sudhir Agrawal , Fu-Gang Zhu
发明人： Daqing Wang , Ekambar Kandimalla , Sudhir Agrawal , Fu-Gang Zhu
IPC分类号： A61K39/395 , A61K39/00 , A61K39/35 , A61K39/39 , A61P37/02
CPC分类号： A61K39/0008 , A61K39/0011 , A61K39/39 , A61K2039/542 , A61K2039/543 , A61K2039/55561
摘要： The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers on mucosal innate immunity as well as adjuvant activity using ovalbumin (OVA) as an antigen through administration to the mucosal lining.
摘要翻译： 本发明涉及免疫刺激性寡核苷酸和/或免疫反应物对粘膜先天免疫的治疗用途以及使用卵白蛋白（OVA）作为抗原通过给予粘膜衬里的佐剂活性。
-
46.发明申请Potent mucosal immune response induced by modified immunomodulatory oligonucleotides 审中-公开由修饰的免疫调节寡核苷酸诱导的强力粘膜免疫应答公开(公告)号：US20050222072A1
公开(公告)日：2005-10-06
申请号：US11060228
申请日：2005-02-17
申请人： Daqing Wang , Ekambar Kandimalla , Sudhir Agrawal , Fu-Gang Zhu
发明人： Daqing Wang , Ekambar Kandimalla , Sudhir Agrawal , Fu-Gang Zhu
CPC分类号： A61K39/0008 , A61K39/0011 , A61K39/39 , A61K2039/542 , A61K2039/543 , A61K2039/55561
摘要： The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers on mucosal innate immunity as well as adjuvant activity using ovalbumin (OVA) as an antigen through administration to the mucosal lining.
摘要翻译： 本发明涉及免疫刺激性寡核苷酸和/或免疫反应物对粘膜先天免疫的治疗用途以及使用卵白蛋白（OVA）作为抗原通过给予粘膜衬里的佐剂活性。
-
47.发明申请SYNERGISTIC TREATMENT OF CANCER USING IMMUNOMERS IN CONJUNCTION WITH CHEMOTHERAPEUTIC AGENTS 审中-公开使用免疫调节剂联合化疗药物治疗癌症的协同治疗公开(公告)号：US20120107303A1
公开(公告)日：2012-05-03
申请号：US13006860
申请日：2011-01-14
申请人： Ekambar R. Kandimalla , Sudhir Agrawal , Daqing Wang , Lakshml Bhagat , Dong Yu
发明人： Ekambar R. Kandimalla , Sudhir Agrawal , Daqing Wang , Lakshml Bhagat , Dong Yu
IPC分类号： A61K39/395 , A61P35/00 , A61K39/385 , A61K31/7088 , A61K39/00
CPC分类号： A61K39/0011 , A61K39/39558 , A61K2039/55561 , C07K16/2887 , C07K16/32 , C07K2317/24 , A61K2300/00
摘要： The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
摘要翻译： 本发明涉及免疫刺激性寡核苷酸和/或免疫组合物与化学治疗剂组合以提供协同治疗效果的治疗用途。
-
48.发明授权公开(公告)号：US08486908B2
公开(公告)日：2013-07-16
申请号：US13299555
申请日：2011-11-18
CPC分类号： C12N15/117 , A61K31/7115 , A61K31/7125 , A61K45/06 , C12N2310/17 , C12N2310/31 , C12N2310/317 , C12N2310/321 , C12N2310/3341 , C12N2310/336 , C12N2310/51 , C12N2310/52 , Y02A50/401 , Y02A50/411 , Y02A50/414 , A61K2300/00
摘要： The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
-
49.发明申请IMMUNE REGULATORY OLIGONUCLEOTIDE (IRO) COMPOUNDS TO MODULATE TOLL-LIKE RECEPTOR BASED IMMUNE RESPONSE 有权免疫调节寡核苷酸（IRO）化合物，以调节基于类似感受器的免疫应答公开(公告)号：US20120128699A1
公开(公告)日：2012-05-24
申请号：US13299555
申请日：2011-11-18
IPC分类号： A61K39/395 , A61K31/7115 , A61K39/00 , A61P37/06 , A61P31/00 , A61P19/02 , A61P7/06 , A61P11/00 , A61P25/00 , C07H21/02 , A61P17/06
CPC分类号： C12N15/117 , A61K31/7115 , A61K31/7125 , A61K45/06 , C12N2310/17 , C12N2310/31 , C12N2310/317 , C12N2310/321 , C12N2310/3341 , C12N2310/336 , C12N2310/51 , C12N2310/52 , Y02A50/401 , Y02A50/411 , Y02A50/414 , A61K2300/00
摘要： The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These TROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
摘要翻译： 本发明提供作为TLR拮抗剂的新型免疫调节寡核苷酸（IRO）及其使用方法。 这些TRO具有独特的序列，其响应于TLR配体或TLR激动剂抑制或抑制TLR介导的信号传导。 该方法可用于预防和治疗癌症，自身免疫性疾病，气道炎症，炎症性疾病，感染性疾病，皮肤病，变态反应，哮喘或由病原体引起的疾病。
-
公开(公告)号：US20200333613A1
公开(公告)日：2020-10-22
申请号：US16815141
申请日：2020-03-11
申请人： Michael Deutsch , Daqing Wang , James Zambuto , Bien Chann , Bryan Lochman
发明人： Michael Deutsch , Daqing Wang , James Zambuto , Bien Chann , Bryan Lochman
摘要： In various embodiments, a wavelength beam combining laser system includes a fast-axis collimation lens that is rotated with respect to a plurality of emitters in order to converge the emitted beams onto a dispersive element and/or reduce the size of the multi-wavelength output beam of the system.
-
-
-
-
-
-
-
-
-
搜索结果
63 条记录 (耗时 0.03 秒)
